Novo Nordisk A/S (NONOF) Comparison with companies in other sectors?

Novo Nordisk A/S has a share price of 4.44B. You can analyze Novo Nordisk A/S (NONOF) competitors across different market sectors through stock heatmaps.

What are NONOF's NET and operating margins?

Novo Nordisk A/S (NONOF) operating margin is around 0.44, and net profit margin is approximately 0.35 as of the latest reports.

In what way does NONOF's earnings per share (EPS) trend reflect its financial momentum?

Novo Nordisk A/S (NONOF) EPS is 3.70 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Novo Nordisk A/S is 17.85, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Novo Nordisk A/S?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Novo Nordisk A/S like P/E which is 17.81, P/B which is 13.45, and PEG which is 0.76. Compare them with sector averages to evaluate if the stock is priced fairly.

Novo Nordisk A/S

NONOF•PNK

Healthcare

Biotechnology

$66.06

$1.55(2.40%)

Fundamental Analysis of Novo Nordisk A/S (NONOF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$3.70

P/E Ratio

17.85

ROE

0.81%

Net Margin

0.35%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$293.25B

Shares OutstandingTotal number of shares issued

$4.44B

Book Value/ShareNet worth per share

$31.21

Revenue/ShareAnnual revenue per share

$68.28

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$3.7

Net MarginNet income as percentage of revenue

34.51%

Operating MarginOperating income as percentage of revenue

44.49%

ROEReturn on shareholders' equity

81.24%

ROAReturn on total assets

21.39%

ROCEReturn on capital employed

53.30%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$16.84

Cash/ShareCash and equivalents per share

$9.36

FCF YieldFree cash flow as percentage of market cap

4.01%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$10.54

Dividend YieldAnnual dividend as percentage of stock price

2.51%

Financial Ratios Analysis data is not available for NONOFFinancial Ratios Analysis details for NONOF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for NONOFSector Benchmarking details for NONOF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Novo Nordisk A/S Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Novo Nordisk A/S. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Novo Nordisk A/S's unique business strengths and challenges.

Key Financial Metrics for Novo Nordisk A/S

For Novo Nordisk A/S, essential financial indicators include EPS 3.70, PE 17.85, and ROE 0.81. These key ratios reveal insights into Novo Nordisk A/S's profitability, valuation, and operational health. Understanding these metrics enables you to compare Novo Nordisk A/S with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Novo Nordisk A/S

Metrics like Net Margin 34.51% and ROA 21.39% shed light on how well Novo Nordisk A/S is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Novo Nordisk A/S can sustain its operations and continue growing in the future.

Valuation and Market Position of Novo Nordisk A/S

Using ratios such as P/B Ratio 13.45 and PEG Ratio 0.76, investors can assess whether Novo Nordisk A/S is appropriately valued based on its financials and growth potential. These figures, combined with Novo Nordisk A/S's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Novo Nordisk A/S

Financial health indicators, such as Debt/Equity Ratio 0.86 and Cash Flow $16.84, provide a snapshot of Novo Nordisk A/S's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Novo Nordisk A/S, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Novo Nordisk A/S

Investing in Novo Nordisk A/S based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Novo Nordisk A/S focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;